Remove Documentation Remove Labelling Remove Webinar
article thumbnail

How to use Pay Per Click Advertising to Reach HCPs in Pharma

Pharma Marketing Network

Conversion Rate: Tracks how many users complete a desired action, such as signing up for a webinar or downloading whitepapers. Avoiding misleading claims or unapproved off-label promotions. Offer incentives like exclusive research reports or webinar invites.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

WebinarsWebinars, whether live streamed or on-demand, can be used for communication with HCPs, HCOs, and POs. A company is responsible for the content of webinars and should take reasonable steps to ensure the audience is targeted and well defined.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Time for FDA’s OPDP to Fill the Gaps on Digital and Social Media

Eye on FDA

The interesting thing in connection with that is that in May – in the midst of the COVID-19 pandemic – FDA held a Webinar on the “ Bad Ad” Program – a program that deputizes healthcare professionals to assess promotional communications and report potential violations to the agency.

article thumbnail

FDA’s New Draft Guidance on 510(k) Implant Devices: What You Need to Know

FDA Law Blog: Biosimilars

By Philip Won & Véronique Li, Senior Medical Device Regulation Expert — As we recently blogged , FDA released three draft guidance documents to help enhance the predictability, consistency, and transparency of the 510(k) program. One of these documents focuses on “ Evidentiary Expectations for 510(k) Implant Devices.”

article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

Clarify What Information is Sought from Speakers Report on Data Utilization Host Educational Webinars Before Listening Sessions Market as Stakeholder Listening Sessions if They Have Broader Representation Improve the Structure of the Listening Sessions. Finally, we encourage CMS to consider a longer time horizon for the submission of data.

article thumbnail

March 2024 Newsletter

Safe Biologics

From the post: The HHS Budget in Brief document describes the policy objective simply enough: “ Permit Biosimilar Substitution without Prior FDA Determination of Interchangeability” and clarifies that this means “deem all approved biosimilars to be interchangeable with their respective reference products”. 1 and go into effect in 2026.

article thumbnail

FDA’s Final Rule on the Implied Nutrient Content Claim “Healthy” Maintains Focus on Foods Rather than on Nutrients

FDA Law Blog: Biosimilars

Under the proposed rule, any raw whole fruits and vegetables could be labeled healthy no matter the level of added sugars, sodium, or saturated fat. FDA also plans to host a stakeholder webinar on the final rule at a later date. The final rule does not limit this exemption to only raw fruits and vegetables.